Bristol Myers Squibb Company is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines for patients with serious diseases. The company's mission is to provide transformative therapies in areas such as oncology, immunology, and cardiovascular disease. Bristol Myers Squibb employs a strategy focused on scientific excellence and collaboration, leveraging cutting-edge research and development to address unmet medical needs. Through its robust pipeline and commitment to patient access, the company aims to improve health outcomes and enhance the quality of life for patients worldwide.

BRISTOL MYERS SQUIBB CO

Bristol-Myers Squibb (BMY) continues to demonstrate strong financial performance amidst looming challenges in the pharmaceutical sector. As of February 6, 2025, BMY reported an impressive fourth-quarter 2024 earnings with adjusted earnings per share (EPS) of $1.67, surpassing Wall Street expectations for the fourth consecutive quarter. Total revenues reached $12.3 billion,...

Bristol-Myers Squibb Shows Strong Financial Growth Despite Upcoming Generic Competition for Key Drugs

Bristol-Myers Squibb showcases impressive financial results, with Q4 2024 earnings surpassing expectations and revenues climbing 8% year-over-year. Yet, as generic competition looms and pricing pressures mount, can BMY maintain its growth trajectory in the face of these challenges?